Neuracle (博睿康) updated its IPO prospectus and regulatory inquiry response, revealing pricing, implant volumes, and long-term clinical data for its invasive brain-computer interface (BCI) product NEO-ONE SCI.
China's invasive BCI is now commercial, and Neuracle's IPO could be a major catalyst for the entire sector.
Free preview — more China A-share & HK research · About Us · Legal & Privacy